medigraphic.com
ISSN 2448-5640 (Impreso)
Diario Oficial de la Sociedad Mexicana de Cirugía Cardiaca, A.C., y del Colegio Mexicano de Cirugía Cardiovascular y Torácica, A.C.

2020, Número 2

<< Anterior Siguiente >>

Cir Card Mex 2020; 5 (2)


Coronary artery bypass grafting and ischemic cardiomyopathy
Pondus atendum postest ut alleviaretur cor ?

Matos-Santana H, Holy JM, Orozco-Hernández EJ

Idioma: Ingles.
Referencias bibliográficas: 31
Paginas: 42-45
Archivo PDF: 134.48 Kb.


RESUMEN

Cardiomiopatia isquémica se define como una disfunción del ventrículo izquierdo , con una fracción de eyección menor o igual al 40% y enfermedad coronaria. El substrato de esta entidad es heterogéneo, una coexistencia combinada entre cicatriz y miocardio normal, hibernante y aturdido, todos hallazgos en la misma región ,representando el mismo proceso en diferentes fases. Es un hecho que la valoración de la isquemia y viabilidad, por si solas, no guían con precisión la indicación de bypass coronario. La relación riesgo/beneficio de la cirugía es delicada y frágil. A fin de definir la mejor estrategia de revascularización, una evaluación critica y cuidadosa, es de vital importancia. La decisión integra una serie de aspectos intrincados, como presentación clínica, viabilidad miocárdica, estado del ventrículo izquierdo y la coronariografía. Cuando los lechos coronarios son adecuados, creemos que el bypass coronario es indicación clase I en esta entidad.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Gheorghiade M, Sopko G, De Luca L, et al. Navigating the crossroads of coronaryartery disease and heart failure. Circulation 2006;114:1202-13.

  2. Khera S, Panza JA. Surgical Revascularization for Ischemic Cardiomyopathy inthe Post-STICH Era. Cardiol Rev 2015;23:153-60.

  3. Kera S, Panza JA. Surgical Revascularization in Older Adults with Ischemic Cardiomyopathy.Heart Failure Clin 2017; 13: 571-80.

  4. Briceno N, Schuster A, Lumley M, et al. Ischaemic cardiomyopathy: pathophysiology,assessment and the role of revascularization. Heart 2016;102: 397–406.

  5. Heusch G, Schulz R. Characterization of hibernating and stunned myocardium.Eur Heart J 1997;18: D102–10.

  6. Grover S, Srinivasan G, Selvanayagam JB. Myocardial Viability Imaging: Does ItStill Have a Role in Patient Selection Prior to Coronary Revascularisation? HeartLung Circ 2012;21:468-79.

  7. Patel H, Mazur W, Williams KA Sr, Kalra DK. Myocardial viability–State of theart: Is it still relevant and how to best assess it with imaging? Trends CardiovascMed 2018: 28; 24-37.

  8. Schinkel AF, Bax JJ, Boersma E, Elhendy A, Roelandt JR, Poldermans D. Howmany patients with ischemic cardiomyopathy exhibit viable myocardium? Am JCardiol 2001;88:561-4.

  9. Schinkel AF, Bax JJ, Poldermans D, Elhendy A, Ferrari R, Rahimtoola SH. Hibernatingmyocardium: diagnosis and patient outcomes. Curr Probl Cardiol2007;327:375-410.

  10. Janardhanan R, Moon JC, Pennell DJ, Senior R. Myocardial contrast echocardiographyaccurately reflects transmurality of myocardial necrosis and predicts contractilereserve after acute myocardial infarction. Am Heart J 2005;149:355-62.

  11. Kirschbaum SW, Rossi A, Boersma E, et al. Combining magnetic resonance viability variables better predicts improvement of myocardial function prior to percutaneouscoronary intervention. Int J Cardiol 2012;159:192-7.

  12. Rizzello V, Poldermans D, Boersma E, et al. Opposite patterns of left ventricularremodeling after coronary revascularization in patients with ischemic cardiomyopathy:role of myocardial viability. Circulation 2004;110:2383-8.

  13. Pegg TJ, Selvanayagam JB, Jennifer J, et al. Prediction of global left ventricularfunctional recovery in patients with heart failure undergoing surgical revascularisation,based on late gadolinium enhancement cardiovascular magnetic resonance.J Cardiovasc Magn Reson 2010;12:56. doi: 10.1186/1532-429X-12-56.

  14. Murphy ML, Hultgren HN, Detre K, et al. Treatment of chronic stable angina.A preliminary report of survival data of the randomized Veterans Administrationcooperative study. N Engl J Med 1977;297: 621–7.

  15. [NO authors listed]. Coronary-artery bypass surgery in stable angina pectoris: survivalat two years. European Coronary Surgery Study Group. Lancet 1979;1:889–93.

  16. [NO authors listed]. Coronary artery surgery study (CASS): a randomized trial ofcoronary artery bypass surgery. Survival data. Circulation 1983;68:939–50.

  17. Alderman EL, Fisher LD, Litwin P, et al. Results of coronary artery surgery inpatients with poor left ventricular function (CASS). Circulation 1983;68: 785–95.

  18. O’Connor CM, Velazquez EJ, Gardner LH, et al. Comparison of coronary arterybypass grafting versus medical therapy on long-term outcome in patients withischemic cardiomyopathy (a 25-year experience from the duke cardiovascular diseasedatabank). Am J Cardiol 2002;90:101-7.

  19. The Veterans Administration Coronary Artery Bypass Surgery Cooperative StudyGroup. Eleven-year survival in the Veterans Administration randomized trial ofcoronary bypass surgery for stable angina. N Engl J Med 1984;311:1333-9.

  20. Varnauskas E. Twelve-year follow-up of survival in the randomized EuropeanCoronary Surgery Study. N Engl J Med 1988;319:332-7.

  21. Allman KC, Shaw LJ, Hachamovitch R,Udelson JE. Myocardial viability testingand impact of revascularization on prognosis in patients with coronary arterydisease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol2002;39:1151-8.

  22. Velazquez EJ, Lee KL, Deja MA, et al. Coronary-artery bypass surgery in patientswith left ventricular dysfunction. N Engl J Med 2011;364:1607-16.

  23. Velazquez EJ, Lee KL, Jones RH, et al. Coronary-artery bypass surgery in patientswith ischemic cardiomyopathy. N Engl J Med 2016;374:1511-20.

  24. Bonow RO, Maurer G, Lee KL, et al. Myocardial viability and survival in ischemicleft ventricular dysfunction. N Engl J Med 2011;364:1617-25.

  25. Panza JA, Holly TA, Asch FM, et al. Inducible myocardial ischemia and outcomesin patients with coronary artery disease and left ventricular dysfunction. J Am CollCardiol 2013;61:1860–70.

  26. Beanlands RS, Nichol G, Huszti E, et al. F-18-fluorodeoxyglucose positron emissiontomography imaging-assisted management of patients with severe left ventriculardysfunction and suspected coronary disease: a randomized, controlled trial(PARR-2). J Am Coll Cardiol 2007;50:2002-12.

  27. Cleland JG, Calvert M, Freemantle N, et al. The heart failure revascularisationtrial (HEART). Eur J Heart Fail 2011;13:227-33.

  28. King’s College L. Study of Efficacy and Safety of Percutaneous Coronary Interventionto Improve Survival in Heart Failure (REVIVED-BCIS2) 2013. Clinical-Trials.gov Identifier: NCT01920048. Last Update Posted: September 13, 2019.

  29. O’Meara E, Mielniczuk LM, Wells GA, DeKemp RA, Klein R, Coyle D, et al.Alternative Imaging Modalities in Ischemic Heart Failure (AIMI-HF) IMAGE HFProject I-A: study protocol for a randomized controlled trial. Trials 2013;14:218.doi: 10.1186/1745-6215-14-218.

  30. Panza JA, Velazquez EJ, She L, et al. Extent of coronary and myocardial diseaseand benefit from surgical revascularization in LV dysfunction. J Am Coll Cardiol2014;64:553-61.

  31. Neumann FJ, Sousa UM, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardialrevascularization. European Heart Journal 2018;40, 87-165.




2020     |     www.medigraphic.com